Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:20:32.898Z.
Calculation as of: 2026-10-06T22:20:32.898Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 017b786e338061c10a4665063360519c0b30ae95494f37f63af909a19a8b52dc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2018-03-29.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
PRICE/OCF RATIO AVG TTM
N/A
PRICE/OCF RATIO AVG 3Y
N/A
PRICE/OCF RATIO AVG 5Y
N/A
PRICE/OCF RATIO AVG 10Y
N/A
PRICE/OCF RATIO AVG 15Y
N/A
PRICE/OCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$58.44M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$59.18M
Price/OCF Ratio
N/A
TTM Avg
2.60
3Y Avg
2.60
5Y Avg
2.60
Market Cap
$57.01M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adicet Bio, Inc. (ACET) | $58.43M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.29M | N/A | N/A | N/A | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $58.06M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.76M | N/A | N/A | N/A | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $59.18M | N/A | 2.60 | 2.60 | 2.60 |
| Talphera, Inc. (TLPH)vs › | $57.61M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.02M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.42M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PRICE/OCF RATIO |
|---|---|
| 2018-03-29 | 54.53 |
| 2018-03-28 | 60.11 |
| 2018-03-27 | 63.98 |
| 2018-03-26 | 62.33 |
| 2018-03-23 | 67.05 |
| 2018-03-22 | 75.02 |
| 2018-03-21 | 83.67 |
| 2018-03-20 | 84.70 |
| 2018-03-19 | 85.78 |
| 2018-03-16 | 85.10 |
| 2018-03-15 | 84.93 |
| 2018-03-14 | 85.84 |
| 2018-03-13 | 87.94 |
| 2018-03-12 | 90.50 |
| 2018-03-09 | 90.50 |
| 2018-03-08 | 92.10 |
| 2018-03-07 | 96.82 |
| 2018-03-06 | 97.90 |
| 2018-03-05 | 100.35 |
| 2018-03-02 | 100.92 |
| 2018-03-01 | 104.56 |
| 2018-02-28 | 110.99 |
| 2018-02-27 | 112.42 |
| 2018-02-26 | 117.26 |
| 2018-02-23 | 118.68 |
| 2018-02-22 | 111.85 |
| 2018-02-21 | 112.08 |
| 2018-02-20 | 110.99 |
| 2018-02-16 | 106.78 |
| 2018-02-15 | 103.71 |
| 2018-02-14 | 102.97 |
| 2018-02-13 | 103.88 |
| 2018-02-12 | 103.03 |
| 2018-02-09 | 96.76 |
| 2018-02-08 | 93.92 |
| 2018-02-07 | 92.33 |
| 2018-02-06 | 91.53 |
| 2018-02-05 | 96.42 |
| 2018-02-02 | 96.99 |
| 2018-02-01 | 95.34 |
| 2018-01-31 | 92.33 |
| 2018-01-30 | 89.59 |
| 2018-01-29 | 92.38 |
| 2018-01-26 | 96.08 |
